Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 68.26 Billion KRW | 19.61% |
| 2022 | 56.6 Billion KRW | -18.51% |
| 2021 | 69.45 Billion KRW | 73.71% |
| 2020 | 39.98 Billion KRW | 2.36% |
| 2019 | 39.06 Billion KRW | 56.53% |
| 2018 | 24.95 Billion KRW | 2346.43% |
| 2017 | 1.02 Billion KRW | -95.37% |
| 2016 | 22.01 Billion KRW | -20.1% |
| 2015 | 27.55 Billion KRW | 12.76% |
| 2014 | 24.43 Billion KRW | 27.69% |
| 2013 | 19.13 Billion KRW | 467.58% |
| 2012 | 3.37 Billion KRW | -65.53% |
| 2011 | 9.78 Billion KRW | -43.36% |
| 2010 | 17.27 Billion KRW | 69.7% |
| 2009 | 10.17 Billion KRW | 29.87% |
| 2008 | 7.83 Billion KRW | -42.9% |
| 2007 | 13.72 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 20.12 Billion KRW | 23.09% |
| 2024 Q3 | 19.45 Billion KRW | -3.31% |
| 2024 Q1 | 16.34 Billion KRW | 15.04% |
| 2023 Q4 | 14.2 Billion KRW | -23.02% |
| 2023 Q1 | 15.99 Billion KRW | 314.33% |
| 2023 Q3 | 18.45 Billion KRW | -3.04% |
| 2023 FY | 67.7 Billion KRW | 19.61% |
| 2023 Q2 | 19.03 Billion KRW | 19.01% |
| 2022 Q2 | 22.95 Billion KRW | -69.93% |
| 2022 FY | 56.6 Billion KRW | -18.51% |
| 2022 Q4 | -7.46 Billion KRW | -121.19% |
| 2022 Q3 | 35.22 Billion KRW | 53.46% |
| 2022 Q1 | 76.33 Billion KRW | 1362.92% |
| 2021 Q2 | 6.51 Billion KRW | -39.45% |
| 2021 Q1 | 10.75 Billion KRW | 132.2% |
| 2021 FY | 69.45 Billion KRW | 73.71% |
| 2021 Q3 | 18.96 Billion KRW | 191.37% |
| 2021 Q4 | 5.21 Billion KRW | -72.49% |
| 2020 Q1 | 13.39 Billion KRW | 110.06% |
| 2020 FY | 39.98 Billion KRW | 2.36% |
| 2020 Q3 | 12.26 Billion KRW | 26.4% |
| 2020 Q4 | 4.63 Billion KRW | -62.24% |
| 2020 Q2 | 9.7 Billion KRW | -27.58% |
| 2019 Q2 | 11.39 Billion KRW | 20.91% |
| 2019 FY | 39.06 Billion KRW | 56.53% |
| 2019 Q1 | 9.42 Billion KRW | 92.87% |
| 2019 Q3 | 11.86 Billion KRW | 4.14% |
| 2019 Q4 | 6.37 Billion KRW | -46.27% |
| 2018 Q4 | 4.88 Billion KRW | -30.71% |
| 2018 Q3 | 7.05 Billion KRW | 68.23% |
| 2018 FY | 24.95 Billion KRW | 2346.43% |
| 2018 Q2 | 4.19 Billion KRW | -52.5% |
| 2018 Q1 | 8.82 Billion KRW | 250.33% |
| 2017 Q3 | 1.24 Billion KRW | 60.23% |
| 2017 Q4 | -5.87 Billion KRW | -570.48% |
| 2017 FY | 1.02 Billion KRW | -95.37% |
| 2017 Q1 | 4.86 Billion KRW | 321.55% |
| 2017 Q2 | 778.73 Million KRW | -83.99% |
| 2016 FY | 22.01 Billion KRW | -20.1% |
| 2016 Q2 | 10.02 Billion KRW | 132.26% |
| 2016 Q3 | 6.51 Billion KRW | -35.0% |
| 2016 Q4 | 1.15 Billion KRW | -82.29% |
| 2016 Q1 | 4.31 Billion KRW | -50.57% |
| 2015 Q4 | 8.73 Billion KRW | 49.31% |
| 2015 Q2 | 7.01 Billion KRW | 17.97% |
| 2015 Q1 | 5.94 Billion KRW | -25.14% |
| 2015 FY | 27.55 Billion KRW | 12.76% |
| 2015 Q3 | 5.84 Billion KRW | -16.66% |
| 2014 Q1 | 5.21 Billion KRW | -24.32% |
| 2014 Q3 | 6.96 Billion KRW | 62.07% |
| 2014 Q4 | 7.94 Billion KRW | 14.05% |
| 2014 Q2 | 4.29 Billion KRW | -17.61% |
| 2014 FY | 24.43 Billion KRW | 27.69% |
| 2013 Q2 | 8.41 Billion KRW | 1482.34% |
| 2013 Q4 | 6.89 Billion KRW | 109.14% |
| 2013 FY | 19.13 Billion KRW | 467.58% |
| 2013 Q1 | 531.65 Million KRW | 118.71% |
| 2013 Q3 | 3.29 Billion KRW | -60.81% |
| 2012 FY | 3.37 Billion KRW | -65.53% |
| 2012 Q1 | 1.8 Billion KRW | 278.31% |
| 2012 Q4 | -2.84 Billion KRW | -198.42% |
| 2012 Q3 | 2.88 Billion KRW | 89.79% |
| 2012 Q2 | 1.52 Billion KRW | -15.69% |
| 2011 Q4 | -1.01 Billion KRW | -146.38% |
| 2011 FY | 9.78 Billion KRW | -43.36% |
| 2011 Q3 | 2.18 Billion KRW | -13.58% |
| 2011 Q2 | 2.52 Billion KRW | -56.69% |
| 2011 Q1 | 5.83 Billion KRW | 557.18% |
| 2010 Q2 | 7.87 Billion KRW | 120.56% |
| 2010 Q1 | 3.57 Billion KRW | 617.17% |
| 2010 FY | 17.27 Billion KRW | 69.7% |
| 2010 Q4 | -1.27 Billion KRW | -118.87% |
| 2010 Q3 | 6.75 Billion KRW | -14.21% |
| 2009 Q3 | 1.74 Billion KRW | -72.28% |
| 2009 Q1 | 2.81 Billion KRW | 60.49% |
| 2009 Q2 | 6.3 Billion KRW | 124.06% |
| 2009 Q4 | -690.7 Million KRW | -139.51% |
| 2009 FY | 10.17 Billion KRW | 29.87% |
| 2008 Q4 | 1.75 Billion KRW | 107.93% |
| 2008 Q1 | 2.95 Billion KRW | 72.16% |
| 2008 Q2 | 1.76 Billion KRW | -40.38% |
| 2008 FY | 7.83 Billion KRW | -42.9% |
| 2008 Q3 | 843.38 Million KRW | -52.2% |
| 2007 FY | 13.72 Billion KRW | 0.0% |
| 2007 Q2 | 3.13 Billion KRW | 37.14% |
| 2007 Q4 | 1.71 Billion KRW | -69.18% |
| 2007 Q1 | 2.28 Billion KRW | 0.0% |
| 2007 Q3 | 5.57 Billion KRW | 78.16% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -18627.043% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 11.205% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 185.804% |
| HANDOK Inc. | 12.57 Billion KRW | -442.714% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 3531.982% |
| Yuhan Corporation | 74.56 Billion KRW | 8.443% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -510.701% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 478.367% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 69.644% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -2133.825% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -375.714% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -11346.462% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -6983.365% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -152.547% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -18627.043% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 980.177% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -1592.446% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 197.594% |
| JW Holdings Corporation | 143.66 Billion KRW | 52.482% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 227.799% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 72.317% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 31.94% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 244.046% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -885.531% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -954.964% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -681.858% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -18627.043% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -39.984% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 48.828% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 31.94% |
| Yuhan Corporation | 74.56 Billion KRW | 8.443% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -226.321% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -2089.874% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -58.779% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 31.94% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -233.264% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -24.235% |
| CKD Bio Corp. | -20.15 Billion KRW | 438.752% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -111.794% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -169.808% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -109.89% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 244.046% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -105.953% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 282.061% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -375.714% |
| JW Lifescience Corporation | 32.09 Billion KRW | -112.726% |